Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

Johannes Drach, MD, Huiqiang Huang, MD, Olga S Samoilova, MD, Andrew Belch, MD, Charles M. Farber, MD PhD, André Bosly, MD PhD, Jan Novak, MD PhD, Jan Zaucha, MD PhD, Angela Dascalescu, MD PhD, Udomsak Bunworasate, MD, Zvenyslava Masliak, MD PhD, Kateryna Vilchevskaya, MD PhD, Tadeusz Robak, MD, Lixia Pei, PhD, Brendan Rooney, PhD, Helgi van de Velde, MD PhD, Franco Cavalli, MD

Blood (2014) 124 (21): 3064.

https://doi.org/10.1182/blood.V124.21.3064.3064

Published: 2014

Journal Articles

Secretome Analyses of Primary Bone Marrow Fibroblasts Isolated From MGUS and Multiple Myeloma Show a Stepwise Occurrence of Alterations.

Johannes Drach, MD, Astrid Slany, Thomas Mohr, Johannes Griss, Christoph C Zielinski, Christopher Gerner

Blood (2009) 114 (22): 1801.

https://doi.org/10.1182/blood.V114.22.1801.1801

Published: 2009

Journal Articles

Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma.

Heinz Ludwig, MD, Zdenek Adam, MD, Elena Tóthová, MD, Roman Hajek, MD, Boris Labar, MD, PhD, Miklós Egyed, MD, PhD, Ivan Spicka, MD, Johannes Drach, MD, Heinz Gisslinger, MD, Ingrid Kuhn, MD, Niklas Zojer, MD, Zoran Birovljev, Axel Hinke, PhD

Blood (2009) 114 (22): 2891.

https://doi.org/10.1182/blood.V114.22.2891.2891

Published: 2009

Journal Articles

Double Transplantation with Melphalan (200 mg/m 2 ) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma

Heinz Ludwig, MD, Ivan Spicka, MD, Werner Linkesch, MD, Richard Greil, Hedwig Kasparu, MD, Eberhard Gunsilius, MD, Josef Thaler, MD, Johannes Drach, MD, Ingrid Kuhn, MD, Adalbert Weiβmann, MD, Axel Hinke, PhD

Blood (2008) 112 (11): 3317.

https://doi.org/10.1182/blood.V112.11.3317.3317

Published: 2008

Journal Articles

Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission.

Ulrich Jaeger, MD, Otto Krieger, MD, Georg Hopfinger, MD, Cathrin Skrabs, MD, Christine Einberger, Veronika Huter, MD, Hubert Hausmaninger, MD, Johannes Drach, MD, Markus Raderer, MD, Michael Woo, Pharm.D, Helen Melzer, PhD, Richard Greil, MD, Michael A Fridrik, MD

Blood (2008) 112 (11): 1997.

https://doi.org/10.1182/blood.V112.11.1997.1997

Published: 2008

Journal Articles

Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS)

Cihan Ay, MD, Rainer Vormittag, MD, Daniela Dunkler, PhD, Ralph Simanek, MD, Alexandru-Laurentiu Chiriac, MD, Johannes Drach, MD, Peter Quehenberger, MD, Oswald Wagner, MD, Christoph Zielinski, MD, Ingrid Pabinger, MD

Blood (2008) 112 (11): 3824.

https://doi.org/10.1182/blood.V112.11.3824.3824

Published: 2008

Journal Articles

Efficacy and Safety of Re-Treatment with Bortezomib (Velcade©) in Patients with Multiple Myeloma: Results from a Prospective International Phase II Trial

Maria Teresa Petrucci, Igor W. Blau, PD, Paolo Corradini, MD, Meletios A. Dimopoulos, Johannes Drach, MD, Pilar Giraldo, MD, PhD, Adriana Teixeira, MD, Joan Blade

Blood (2008) 112 (11): 3690.

https://doi.org/10.1182/blood.V112.11.3690.3690

Published: 2008

Journal Articles

Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission.

Johannes Drach, MD, Hannes Kaufmann, MD, Oskar Pichelmayer, MD, Verena Sagaster, MD, Sonja Holzer, MD, Viktoria Odelga, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2007) 110 (11): 2578.

https://doi.org/10.1182/blood.V110.11.2578.2578

Published: 2007

Journal Articles

Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis.

Viktoria Odelga, MD, Jutta Ackermann, Verena Sagaster, MD, Hannes Kaufmann, MD, Christoph Zielinski, MD, Johannes Drach, MD

Blood (2007) 110 (11): 4845.

https://doi.org/10.1182/blood.V110.11.4845.4845

Published: 2007

Journal Articles

Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.

Heinz Ludwig, MD, Elena Tothova, MD, Roman Hajek, MD, Johannes Drach, MD, Zdenek Adam, MD, Boris Labar, MD, Miklós Egyed, MD, Ivan Spicka, MD, Heinz Gisslinger, MD, Ingrid Kuhn, MD, Axel Hinke, PhD

Blood (2007) 110 (11): 529.

https://doi.org/10.1182/blood.V110.11.529.529

Published: 2007

Journal Articles

A Cellular Proteome Map of Human Multiple Myeloma.

Johannes Drach, MD, Astrid Slany, Verena Sagaster, MD, Nina Gundacker, Verena Haudek, Viktoria Odelga, Helge Wimmer, Christoph Zielinski, MD, Christopher Gerner, MD

Blood (2007) 110 (11): 111.

https://doi.org/10.1182/blood.V110.11.111.111

Published: 2007

Journal Articles

Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma.

Johannes Drach, MD, Hannes Kaufmann, MD, Oskar Pichelmayer, MD, Verena Sagaster, MD, Sonja Seidl, MD, Andreas Chott, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2006) 108 (11): 2753.

https://doi.org/10.1182/blood.V108.11.2753.2753

Published: 2006

Journal Articles

Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m 2 ) and Triple T with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma (An Interim Analysis).

Heinz Ludwig, MD, Werner Linkesch, MD, Hedwig Kasparu, MD, Otto Krieger, MD, Ivan Spicka, MD, Gunther Gastl, MD, Richard Greil, MD, Johannes Drach, MD, Josef Thaler, MD, Ingrid Kuhn, Niklas Zojer, MD, Axel Hinke, PhD

Blood (2006) 108 (11): 3083.

https://doi.org/10.1182/blood.V108.11.3083.3083

Published: 2006

Journal Articles

Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma.

Johannes Drach, MD, Verena Sagaster, MD, Victoria Odelga, MD, Hannes Kaufmann, MD, Jutta Ackermann, Markus Galhuber, Niklas Zojer, MD, Elisabeth Küenburg, MD, Christoph Zielinski, MD, Rotraud Wieser, MD, Heinz Ludwig, MD

Blood (2006) 108 (11): 3398.

https://doi.org/10.1182/blood.V108.11.3398.3398

Published: 2006

Journal Articles

Thalidomide-Dexamethasone Versus Melphalan-Prednisolone as First Line Treatment in Elderly Patients with Multiple Myeloma: An Interim Analysis.

Heinz Ludwig, MD, Johannes Drach, MD, Elena Tóthová, MD, Heinz Gisslinger, MD, Werner Linkesch, MD, Boris Jaksic, MD, Michael Fridik, MD, Josef Thaler, MD, Alois Lang, MD, Roman Hajek, MD, Niklas Zojer, MD, Richard Greil, MD, Ingrid Kuhn, Axel Hinke, Boris Labar, MD

Blood (2005) 106 (11): 782.

https://doi.org/10.1182/blood.V106.11.782.782

Published: 2005

Journal Articles

Promising Activity of Bortezomib, Rituximab, and Dexamethason (BORID) in Patients with Relapsed Mantle Cell Lymphoma.

Johannes Drach, MD, Sonja Seidl, MD, Oskar Pichelmayer, MD, Hannes Kaufmann, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2005) 106 (11): 4799.

https://doi.org/10.1182/blood.V106.11.4799.4799

Published: 2005

Journal Articles

Short Survival, Despite Promising Response Rates, after Bortezomib Treatment of Multiple Myeloma Patients with a 13q-Deletion.

Johannes Drach, MD, E. Kuenburg, MD, Verena Sagaster, MD, Niklas Zojer, MD, Hannes Kaufmann, MD, Jutta Ackermann, Heinz Ludwig, MD

Blood (2005) 106 (11): 509.

https://doi.org/10.1182/blood.V106.11.509.509

Published: 2005

Journal Articles

The Chromosomal Pattern 14q-Translocation Plus 13q-Deletion Is Characteristic for Multiple Myeloma after a Preceding Monoclonal Gammopathy of Undetermined Significance.

Johannes Drach, MD, Jutta Ackermann, Catrin Baldia, MD, Hannes Kaufmann, MD, Thomas Noesslinger, MD, Heinz Gisslinger, MD, Sonja Seidl, MD, Verena Sagaster, MD, Andrea Keck, MD, Heinz Ludwig, MD, Ulrich Jaeger, MD, Christoph Zielinski, MD

Blood (2004) 104 (11): 4873.

https://doi.org/10.1182/blood.V104.11.4873.4873

Published: 2004

Journal Articles

Microvessel Endothelial Cells of Hematological Malignancies Harbor Disease Specific Genetic Aberrations.

Ilse Schwarzinger, MD, Markus Exner, MD, Harald Esterbauer, MD, Johannes Drach, MD, Ulrich Jaeger, MD, Andreas Chott, MD, Oswald Wagner, MD, Berthold Streubel, MD

Blood (2004) 104 (11): 544.

https://doi.org/10.1182/blood.V104.11.544.544

Published: 2004

Journal Articles

Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q.

Hannes Kaufmann, MD, Catrin Baldia, MD, Jutta Ackermann, Thomas Noesslinger, MD, Heinz Gisslinger, MD, Ulrich Jaeger, MD, Verena Sagaster, MD, Sonja Seidl, MD, Andrea Keck, MD, Heinz Ludwig, MD, Ingrid Simonitsch-Klupp, MD, Christoph Zielinski, MD, Johannes Drach, MD

Blood (2004) 104 (11): 3459.

https://doi.org/10.1182/blood.V104.11.3459.3459

Published: 2004

NARROW

Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

Secretome Analyses of Primary Bone Marrow Fibroblasts Isolated From MGUS and Multiple Myeloma Show a Stepwise Occurrence of Alterations.

Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma.

Double Transplantation with Melphalan (200 mg/m 2 ) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma

Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission.

Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS)

Efficacy and Safety of Re-Treatment with Bortezomib (Velcade©) in Patients with Multiple Myeloma: Results from a Prospective International Phase II Trial

Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission.

Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis.

Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.

A Cellular Proteome Map of Human Multiple Myeloma.

Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma.

Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m 2 ) and Triple T with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma (An Interim Analysis).

Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma.

Thalidomide-Dexamethasone Versus Melphalan-Prednisolone as First Line Treatment in Elderly Patients with Multiple Myeloma: An Interim Analysis.

Promising Activity of Bortezomib, Rituximab, and Dexamethason (BORID) in Patients with Relapsed Mantle Cell Lymphoma.

Short Survival, Despite Promising Response Rates, after Bortezomib Treatment of Multiple Myeloma Patients with a 13q-Deletion.

The Chromosomal Pattern 14q-Translocation Plus 13q-Deletion Is Characteristic for Multiple Myeloma after a Preceding Monoclonal Gammopathy of Undetermined Significance.

Microvessel Endothelial Cells of Hematological Malignancies Harbor Disease Specific Genetic Aberrations.

Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only